Evidence map›Paper›PMID 27814341›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2016

Association Between microRNA-125a rs12976445 C>T Polymorphism and 18F-Fluorodeoxyglucose (18FDG) Uptake: Clinical and Metabolic Response in Patients with Non-Small Cell Lung Cancer.

Zhina Zang, Wenhua Guan, Diansen Chen, Yan Han, Zhan Shi, Jinjin Zhou

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Zhina ZangDepartment of Nuclear Medicine, The Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China (mainland).
Wenhua GuanDepartment of Nuclear Medicine, The Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China (mainland).
Diansen ChenDepartment of Medical Imaging, The Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China (mainland).
Yan HanDepartment of Medical Imaging, The Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China (mainland).
Zhan ShiDepartment of Medical Imaging, The Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China (mainland).
Jinjin ZhouDepartment of Medical Imaging, The Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China (mainland).
Henan University of Science and Technology · CNFirst Affiliated Hospital of Henan University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND MicroRNA-125a (miR-125a) has been involved with many diseases, such as hepatocellular carcinoma and inflammation. In this study, we aimed to investigate the molecular mechanism, including the potential regulator and signaling pathways, of vascular endothelial growth factor (VEGF). MATERIAL AND METHODS We divided the participants into 3 groups by rs12976445 genotype and performed chi-square tests to evaluate the differences between CC and CT+TT groups for sex, age, grading, pT category, metastases, and fludeoxyglucose F18 injection (18FDG) metabolism. RESULTS We found all variables to be statistically significant. We searched the miRNA database online (www.mirdb.org) with the "seed sequence" located within the 3-prime untranslated region (3' UTR) of the target gene and then validated VEGF to be the direct gene via luciferase reporter assay system. We also established the negative regulatory relationship between MiR-125a and VEGF by studying the relative luciferase activity. We conducted real-time polymerase chain reaction and Western blot analysis to study the mRNA and protein expression level of VEGF among different groups (CC=18, CT=8, TT=3) or cells treated with scramble control, miR-125a mimics, VEGF RNA, and MiR-125a inhibitors. CONCLUSIONS We validated the negative regulatory relationship between MiR-125a and VEGF and found that rs12976445 may function as a biomarker to predict metabolism of 18FDG.

Indexed as

Genetic Association StudiesGenetic Predisposition to DiseaseA549 CellsBase SequenceCarcinoma, Non-Small-Cell LungDemographyFemaleFluorodeoxyglucose F18Gene Expression Regulation, NeoplasticGenes, ReporterHumansLuciferasesLung NeoplasmsMaleMicroRNAsMiddle AgedFluorodeoxyglucose F18LuciferasesMicroRNAsMIRN125 microRNA, humanVascular Endothelial Growth Factor A

Identifiers

PMID27814341
PMCPMC5100836
OpenAlexW2548876206

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.